Lindbrook Capital’s Neumora Therapeutics NMRA Stock Holding History

Lindbrook Capital’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-48	Closed	-$509	–	2895
2024 Q4	$509	Buy	+48	New	+$575	﹤0.01%	2618

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Lindbrook Capital's NMRA Position: Q1 2025 in Review

Lindbrook Capital sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 48 shares — an estimated $509 sold.

Lindbrook Capital first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $509 in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

Lindbrook Capital reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 48 Neumora Therapeutics shares in Q1 2025, an estimated $509.
Lindbrook Capital first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
Lindbrook Capital's Neumora Therapeutics position peaked at $509 in Q4 2024.
115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.